Yahoo Finance Results
- Zacks via Yahoo FinanceJun 05 12:49 PM
Immunomedics, Inc. IMMU was a big mover last session, as the company saw its shares rise more than 10% on the day. The move came on solid volume too with far more shares changing ...
Antibody Drug Conjugate Market Size 2018 | Climb at a CAGR of 19% by 2023 with Foremost Players - Available MarketResearchFuture.comMarket Watch3 days ago
- MSN News6 days ago
- Benzinga2 days ago
Benzinga's Daily Biotech Pulse: Mylan's Neulasta Biosimilar Approved, Portola's CEO To Retire, Regenxbio To Join S&P SmallCap IndexBenzinga via Yahoo FinanceJun 05 12:05 PM
Genomic Health, Inc. NASDAQ: GHDX) Haemonetics Corporation (NYSE: HAE) Heron Therapeutics Inc (NASDAQ: HRTX) Immunomedics, Inc. NASDAQ: IMMU) Jazz Pharmaceuticals ...
- Benzinga via Yahoo FinanceJun 04 17:18 PM
The American Society of Clinical Oncology annual meeting started Friday at McCormick Place in Chicago and is set to conclude Tuesday. With several companies presenting on their respective cancer ...
- Benzinga via Yahoo FinanceJun 03 23:27 PM
Phase 2 data for a Keytruda and chemo combo for first-line non-squamous NSCLC. Data for Keytruda and carboplatin-paclitaxel or nab-paclitaxel from the KEYNOTE-407 study evaluating the combo ...
Benzinga's Daily Biotech Pulse: Galmed Rips Higher On Positive NASH Data, Enzo Biochem Falls On Earnings, Pfenex Licenses...Benzinga via Yahoo FinanceJun 12 12:47 PM
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 11) ABIOMED, Inc. (NASDAQ: ABMD ) AngioDynamics, Inc. (NASDAQ: ...
Pipeline - Immunomedics
Immunomedics Inc. stock price, stock quotes and financial overviews from MarketWatch.
Immunomedics, Inc. (IMMU) News – Find the latest company news headlines for Immunomedics, Inc. and all the companies you research at NASDAQ.com
Immunomedics Inc. financial and business news, updates, and information from The New York Times and other leading providers.
Interactive Chart for Immunomedics, Inc. (IMMU), analyze all the data with a huge range of indicators.
Immunomedics announced data from a phase 2 study that tested its lead compound sacituzumab govitecan as a potential treatment for metastatic triple-negative breast cancer (mTNBC). Data from the 110 patient study showed that sacituzumab govitecan elicited an objective response rate of 31%, with ...
Stock quote for Immunomedics, Inc. Common Stock Common Stock (IMMU) with real-time last sale and extended hours stock prices, company news, charts, and research at Nasdaq.
Learn about working at Immunomedics. Join LinkedIn today for free. See who you know at Immunomedics, leverage your professional network, and get hired.